GGrantIndex
Sort

82,697 grants matching vaccine development

Coxiella burnetii immunobiology, host-pathogen modeling, and countermeasure development

$1,494,396
Carrie Mae Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

Task V32: Manufacturing and Characterization Services for Universal Influenza Vaccines.

$1,494,007
Sangeetha Sagar · International Aids Vaccine Initiative · N01 · FY2023 · AI

Cellular Vaccines for Cancer Therapy

$1,493,946
University Of Michigan At Ann Arbor · P01 · FY2004 · CA

DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA)

$1,493,832
Elizabeth Norton · Tulane University Of Louisiana · N01 · FY2025 · AI

Role of inflammation, innate resistance, and immunity in carcinogenesis.

$1,493,249
Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Structural Biology Of Virus Assembly

$1,493,212
Alasdair C. Steven · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2018 · AR

San Francisco Bay Clinical Trials Unit

$1,493,196
Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2018 · AI

Lactoferrin as an Adjuvant for Cellular Immunity

$1,493,024
Jeffrey K Actor · Pharmareview Corporation · R42 · FY2009 · AI

Vaccine and Treatment Evaluation Units

$1,492,854
Nadine Georges Rouphael · Emory University · UM1 · FY2022 · AI

ETIB Clinical Research Core

$1,492,154
Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2015 · CA

UPR/MDACC: Partnership for Excellence in Cancer Research (2 of 2)

$1,491,986
Brad R Weiner · University Of Puerto Rico Med Sciences · U54 · FY2022 · CA

PItt-Ohio State-Georgetown Clinical Trials Unit

$1,491,683
John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2017 · AI

PItt-Ohio State-Georgetown Clinical Trials Unit

$1,491,683
John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2016 · AI

Coccidiodes immitis Genome Sequencing Project

$1,491,588
Institute For Genomic Research · U01 · FY2001 · AI

Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis

$1,491,583
Rhea N Coler · Access To Advanced Health Institute · U01 · FY2009 · AI

Chicago Clinical Trials Unit

$1,491,481
Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2018 · AI

Chicago Clinical Trials Unit

$1,491,481
Robert L. Murphy · Northwestern University At Chicago · UM1 · FY2016 · AI

New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae

$1,491,415
Denis Marc Daigle · Venatorx Pharmaceuticals, Inc. · R01 · FY2019 · AI

Immunology And Pathology Of Murine Leukemia Virus Infections

$1,491,179
Kim Hasenkrug · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

TNPRC Breeding Colony Expansion in Support of COVID-19 Research

$1,490,575
Lee Hamm · Tulane University Of Louisiana · P51 · FY2021 · OD

San Francisco Bay Clinical Trials Unit

$1,490,310
Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2017 · AI

WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNIT

$1,490,118
David B Clifford · Washington University · U01 · FY2007 · AI

Immune Regulation in Mycobacterial and Fungal Infections

$1,489,921
Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Complete Genome Variation in Africans with Extreme HIV-1 Transmission Phenotypes

$1,489,907
Jairam Rao Lingappa · University Of Washington · R01 · FY2012 · AI

Influenza Vaccine Development

$1,489,572
Gary J Nabel · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI